ICARIA-MM: Infusion-related reactions* were mostly mild to moderate for patients receiving SARCLISA1

Adapted from SARCLISA Summary of Product Characteristics.1

The most common symptoms of an infusion-related reaction included dyspnoea, cough, chills, and nausea. The most common severe signs and symptoms included hypertension and dyspnoea. The adverse event of severe anaphylactic reaction has been reported as a serious infusion reaction in 5 patients (0.3%) based on data from multiple clinical trials investigating isatuximab.1

In patients who experience grade 2 (moderate) infusion-related reactions, a temporary interruption in the infusion should be considered.1

You are now leaving the website.

By clicking on this link, you will be leaving this Sanofi hosted website, and, depending on the link, will be redirected to either another Sanofi website (for example, to view the Sanofi Privacy Policy) or an independent third-party website.
Sanofi has no control over the content or availability of third-party sites or resources that are linked to, and accepts no liability or responsibility for them or for any loss or damage that may arise from your use of them. The existence of a link between this website and any third party site or resource in no way implies that Sanofi in any way approves of the content of these sites or resources, or any use to which such content maybe put.

Please ensure that you read the legal and privacy policy sections of any website to which you link.